Fellow investors it looks to me like management has been busy getting their ducks in a row. Cleaning up notes and debt. Using restricted shares and the CEO himself adding a huge chunk. We see almost 30% shares held by insiders.

Are they preparing for something much larger here. I still believe A 2018 BUY OUT IS IN THE WORKS!!!

The "ED" rollout continues and the WORD IS GETTING OUT with Creative Medical Technology Holdings gave the Keynote Speaker at Gathering of Health Care Innovators.
The Company's Stem Cell Therapies to be Main Subject at Dr . James Veltmeyer's Congressional Health Care Symposium.

From March 2, 2018 through April 12, 2018, we issued an aggregate of 144,585,823 shares upon the conversions of outstanding notes and 92,023,304 shares upon the cashless exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933. As a result of these issuances, we have outstanding 480,035,712 shares of common stock as of April 12, 2018.

TOTAL O/S: 480,035,712 This number matches the O/S number used to calculate the insider percentages above

Creative Medical Technology Holdings, Inc. (OTCQB: CELZ ) announced today that debt to affiliate company Creative Medical Health, Inc. in the amount of $136,003.00 is being converted to restricted common shares of stock in Creative Medical Technology Holdings, Inc.

"As we certainly have confidence in the fundamentals of Creative Medical Technology Holdings, Inc., in our stem cell technology and in the experience and ability of our network of doctors, scientists and our executives we have determined that this is a prudent action to eliminate additional debt and to continue to build shareholder value.

And as a reminder, May 18-20 we'll be at the American Urological Association (AUA) conference at booth 5870 presenting our CaverstemTM erectile dysfunction technology. Our team is excited and ready to go!"